Immune function, mutant frequency, and cancer risk in the DNA repair defective genodermatoses xeroderma pigmentosum, Cockayne's syndrome, and trichothiodystrophy.
There is evidence for defective DNA repair in xeroderma pigmentosum, Cockayne's syndrome, and trichothiodystrophy, but for increased cancer risk only in xeroderma pigmentosum. Natural and adaptive immune surveillance and mutant frequency to 6-thioguanine resistance in circulating T-lymphocytes were studied in five patients with xeroderma pigmentosum, two with Cockayne's syndrome, and one with trichothiodystrophy. Forty-eight-hour cutaneous hypersensitivity responses to recall antigens excluded anergy and circulating CD3+, CD4+, CD8+, and CD16+ cell numbers were within normal limits in all patients tested, as were proliferative lymphocyte responses to PHA, except in the trichothiodystrophy patient. Proliferative responses to recall antigens (PPD, SKSD, and Candida) showed that all patients responded to one or more antigens. Direct natural killer cytotoxicity measured against the human erythromyeloid leukaemia cell line K562 using a 4-h 51Cr release assay was significantly reduced in xeroderma pigmentosum (specific cytotoxicity less than mean +/- SD greater than 17.4 +/- 9.4 per cent, with effector:target cell ratio of 50:1) compared to normal controls (45.8 +/- 17.8), but normal in Cockayne's syndrome and trichothiodystrophy. Generation of lymphokine activated killer cell activity was normal in the two xeroderma pigmentosum lines tested. The mutant frequency in the xeroderma pigmentosum donors was significantly increased (p less than 0.01) and was elevated in the two Cockayne's syndrome donors, taking age into account. No mutants were observed from the single trichothiodystrophy donor. These findings suggest that reduced natural killer cell activity may contribute to the greatly increased susceptibility to skin cancer in xeroderma pigmentosum.
Norris
P G
PG
Photobiology Unit, St. Thomas' Hospital, London, United Kingdom.
Limb
G A
GA
Hamblin
A S
AS
Lehmann
A R
AR
Arlett
C F
CF
Cole
J
J
Waugh
A P
AP
Hawk
J L
JL
D015703:Antigens, CD / Q000032:analysis; D003057:Cockayne Syndrome / Q000150:complications / Q000235:genetics / Q000276:immunology*; D003602:Cytotoxicity, Immunologic; D004260:DNA Repair; D004392:Dwarfism / Q000276:immunology*; D005260:Female; D006201:Hair Diseases / Q000276:immunology; D006801:Humans; D007057:Ichthyosis / Q000276:immunology; D007107:Immune System / Q000503:physiopathology*; D015979:Killer Cells, Lymphokine-Activated / Q000502:physiology; D007694:Killer Cells, Natural / Q000502:physiology; D008213:Lymphocyte Activation; D008214:Lymphocytes / Q000276:immunology; D008297:Male; D009154:Mutation; D009369:Neoplasms / Q000209:etiology*; D012307:Risk Factors; D012871:Skin Diseases / Q000150:complications / Q000235:genetics* / Q000276:immunology; D012882:Skin Tests; D014983:Xeroderma Pigmentosum / Q000150:complications / Q000235:genetics / Q000276:immunology*
D015703:Antigens, CD